Designing non-clinical safety evaluation programmes for gene therapy products: A personal view

1. While the objectives of risk assessment are common to both gene therapy products and products for other therapies, the methods used may differ greatly. Those for gene therapy frequently will require both the development of techniques and the assessment of endpoints unique to the particular therapy under evaluation. Conventional approaches to toxicity evaluation may be inappropriate.